Paliperidone Extended-Release Tablets 1.5 mg, 3 mg, 6 mg, 9 mg Suppliers & Bulk Manufacturers
Available Forms: Extended-Release Tablets
Available Strengths: 1.5 mg, 3 mg, 6 mg, 9 mg
Reference Brands: Invega®(US & EU)
Category: Antipsychotropic Drugs
Paliperidone is an atypical antipsychotic that works by blocking dopamine D2 and serotonin 5-HT2A receptors, helping to reduce symptoms of schizophrenia and improve mood stability. The extended-release (ER) tablets use an OROS delivery system to provide steady plasma levels over 24 hours, minimizing fluctuations and side effects. They are used for the treatment of schizophrenia and schizoaffective disorder in adults.
Product Description: Paliperidone extended-release tablets (brand name: Invega) are FDA-approved in the United States for the treatment of schizophrenia and schizoaffective disorder in adults. In the European Union, they are authorized under the centralized procedure for schizophrenia. Regulatory requirements include GMP-compliant manufacturing, osmotic-controlled release oral delivery system (OROS) data, and comprehensive clinical efficacy and safety studies. The product labeling in the U.S. includes a boxed warning for increased mortality in elderly patients with dementia-related psychosis. EU authorization also mandates Risk Management Plans (RMPs) and post-marketing safety monitoring. To explore dossier-ready Paliperidone ER tablets, visit Pharmatradz.com.
Paliperidone Extended-Release Tablets — third party manufacturing & bulk supply
Paliperidone Extended-Release Tablets 1.5 mg, 3 mg, 6 mg, 9 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Indicative minimum order quantity
Paliperidone Extended-Release Tablets is supplied as Extended-Release Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Paliperidone Extended-Release Tablets listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Paliperidone Extended-Release Tablets →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Related Products
Lithium Carbonate
Strength:
150 mg, 300 mg, 600 mg
Form: Tablets
Reference Brands: Lithobid (USA/LATAM), Priadel (EU)
View Details
Phenobarbital Sodium
Strength:
65 mg/mL, 130 mg/mL.
Form: Injection
Reference Brands: Generic formulations marketed under different names
View DetailsQuick Response Guaranteed | Verified Suppliers
